A Principal Component of Quality of Life Measures Is Associated with Survival for Head and Neck Cancer Patients Treated with Radiation Therapy.
head and neck neoplasms
principal component analysis
quality of life
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Mar 2021
08 Mar 2021
Historique:
received:
03
02
2021
revised:
19
02
2021
accepted:
26
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Health-related quality of life (HRQOL) metrics can be associated with survival in head and neck cancer (HNC); however, the impact of HRQOL recovery and the relevant HRQOL domains regarding outcome are unclear. Using a single-institution database, we retrospectively reviewed HNC patients treated with definitive or postoperative radiation therapy between 2013 and 2018. The recovery of individual HRQOL domains were determined by the ratio of the post-treatment to baseline scores. Univariate and Multivariate Cox regression were used to analyze survival outcomes. Principal component analysis was used to adjust for multicollinearity of HRQOL domains. In 218 HNC patients who received radiation therapy, median follow-up was 24.8 months (interquartile range (IQR) 14.5-32.0). Principal component analysis evaluating the recovery of HRQOL domains revealed two independent principal components (PC), PC1 and PC2. PC1, which received contributions from the functional domains; physical (PF), role (RF), emotional (EF), cognitive (CF), and global health status (GQOL) was significantly associated with disease-free (HR = 0.77, 95% CI 0.61-0.98, Our study provides evidence that post-treatment recovery of HRQOL domains were associated with overall survival (OS) in HNC. PC1 is an attractive clinical tool to assess the recovery across multiple different HRQOL and the relationship with survival. Future prospective studies may identify patients who could benefit from additional rehabilitation based on PC1 score.
Sections du résumé
BACKGROUND
BACKGROUND
Health-related quality of life (HRQOL) metrics can be associated with survival in head and neck cancer (HNC); however, the impact of HRQOL recovery and the relevant HRQOL domains regarding outcome are unclear.
METHODS
METHODS
Using a single-institution database, we retrospectively reviewed HNC patients treated with definitive or postoperative radiation therapy between 2013 and 2018. The recovery of individual HRQOL domains were determined by the ratio of the post-treatment to baseline scores. Univariate and Multivariate Cox regression were used to analyze survival outcomes. Principal component analysis was used to adjust for multicollinearity of HRQOL domains.
RESULTS
RESULTS
In 218 HNC patients who received radiation therapy, median follow-up was 24.8 months (interquartile range (IQR) 14.5-32.0). Principal component analysis evaluating the recovery of HRQOL domains revealed two independent principal components (PC), PC1 and PC2. PC1, which received contributions from the functional domains; physical (PF), role (RF), emotional (EF), cognitive (CF), and global health status (GQOL) was significantly associated with disease-free (HR = 0.77, 95% CI 0.61-0.98,
CONCLUSION
CONCLUSIONS
Our study provides evidence that post-treatment recovery of HRQOL domains were associated with overall survival (OS) in HNC. PC1 is an attractive clinical tool to assess the recovery across multiple different HRQOL and the relationship with survival. Future prospective studies may identify patients who could benefit from additional rehabilitation based on PC1 score.
Identifiants
pubmed: 33800256
pii: cancers13051155
doi: 10.3390/cancers13051155
pmc: PMC7962523
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : 5P30CA016056-42
Pays : United States
Organisme : NCI NIH HHS
ID : 1P01CA234212
Pays : United States
Références
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Oral Oncol. 2020 Jun 16;109:104854
pubmed: 32559724
World J Clin Oncol. 2012 Apr 10;3(4):57-62
pubmed: 22553505
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Eur Arch Otorhinolaryngol. 2020 May;277(5):1515-1523
pubmed: 32062743
J Clin Oncol. 2009 Jun 20;27(18):2970-6
pubmed: 19451440
Head Neck. 2019 Nov;41(11):3924-3932
pubmed: 31435980
Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):27-31
pubmed: 16415425
JAMA Otolaryngol Head Neck Surg. 2013 Jan;139(1):14-20
pubmed: 23329087
Oral Oncol. 2015 Jan;51(1):1-11
pubmed: 25262163
Arch Otolaryngol Head Neck Surg. 2008 Sep;134(9):958-64
pubmed: 18794441
J Clin Oncol. 2008 Jun 1;26(16):2754-60
pubmed: 18509185
Cancer. 2014 Jan 15;120(2):302-11
pubmed: 24127333
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):662-666
pubmed: 28244404
J Natl Cancer Inst Monogr. 2004;(33):155-67
pubmed: 15504926
Radiother Oncol. 2010 Nov;97(2):258-62
pubmed: 20189668
CA Cancer J Clin. 2021 Feb 4;:
pubmed: 33538338
Laryngoscope. 2016 Dec;126(12):2733-2738
pubmed: 27346612
Value Health. 2013 Jul-Aug;16(5):848-54
pubmed: 23947980
Head Neck. 2009 Jan;31(1):64-76
pubmed: 18972411
JAMA Netw Open. 2020 Jun 1;3(6):e207199
pubmed: 32602907
J Clin Oncol. 2008 Apr 20;26(12):2020-6
pubmed: 18421055
J Clin Oncol. 2008 Mar 10;26(8):1355-63
pubmed: 18227528
JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1136-1146
pubmed: 33090191
Health Qual Life Outcomes. 2011 Aug 03;9:62
pubmed: 21812962
Stat Med. 2002 Dec 30;21(24):3865-84
pubmed: 12483772
Eur Arch Otorhinolaryngol. 2018 Jan;275(1):207-217
pubmed: 29159750
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Eur J Cancer. 2002 Jul;38(10):1351-7
pubmed: 12091066
Pancreatology. 2016 Nov - Dec;16(6):1106-1112
pubmed: 27600995
Support Care Cancer. 2015 Dec;23(12):3645-52
pubmed: 26314706
Nat Biotechnol. 2008 Mar;26(3):303-4
pubmed: 18327243
Head Neck. 2013 May;35(5):684-8
pubmed: 22619040
Eur J Cancer. 2016 Oct;66:138-43
pubmed: 27573427